METHOD OF COMBINED RADIONUCLIDE THERAPY OF DIFFERENTIATED THYROID CANCER WITH METASTATIC INVOLVEMENT OF LUNGS AND SKELETON Russian patent published in 2024 - IPC A61M36/00 A61K51/02 A61P35/04 

FIELD: medicine; radiology.

SUBSTANCE: invention can be used in combined radionuclide therapy of differentiated thyroid cancer with metastatic involvement of lungs and skeleton. Method involves introduction of ¹⁵³Sm-oxabifor and Na¹³¹I. On the first day, a solution of an osteotropic radiopharmaceutical drug (RPD) is administered intravenously: ¹⁵³Sm-oxabifor—18–37 MBq/kg, and 24 hours later, the RPD distribution in the metastatic foci is assessed by SPECT/CT. On 2nd day, an aqueous solution of Na¹³¹I is administered orally—55–74 MBq/kg, after 72 hours, the distribution of Na¹³¹I in the metastatic foci is assessed by SPECT/CT. Subsequent courses of combined radionuclide therapy are performed every 4 months until clinical effect occurs.

EFFECT: use of the invention enables to provide simultaneous exposure to iodine-positive and iodine-negative metastatic foci in the skeleton, thereby increasing the effectiveness of the combined treatment as a whole, without exceeding a single permissible radiation exposure on the red bone marrow, and also provides a double therapeutic effect on metastatic bone centers: radiometabolic (¹⁵³Sm-oxabifor) and radio-targeted (Na¹³¹I), including at multidirectional accumulation of data of said isotopes included in RPD.

1 cl, 2 ex